- Home
- EVAX vs SNSE Comparison
EVAX vs SNSE Comparison
Compare EVAX & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- SNSE
- Stock Information
- Founded
- EVAX 2008
- SNSE 2005
- Country
- EVAX Denmark
- SNSE United States
- Employees
- EVAX 49
- SNSE N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- SNSE Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- SNSE Health Care
- Exchange
- EVAX Nasdaq
- SNSE Nasdaq
- Market Cap
- EVAX 8.7M
- SNSE 12.3M
- IPO Year
- EVAX 2021
- SNSE 2021
- Fundamental
- Price
- EVAX $1.46
- SNSE $0.52
- Analyst Decision
- EVAX Strong Buy
- SNSE Strong Buy
- Analyst Count
- EVAX 2
- SNSE 3
- Target Price
- EVAX $11.00
- SNSE $4.33
- AVG Volume (30 Days)
- EVAX 41.4K
- SNSE 397.3K
- Earning Date
- EVAX 10-31-2024
- SNSE 11-14-2024
- Dividend Yield
- EVAX N/A
- SNSE N/A
- EPS Growth
- EVAX N/A
- SNSE N/A
- EPS
- EVAX N/A
- SNSE N/A
- Revenue
- EVAX $3,295,000.00
- SNSE N/A
- Revenue This Year
- EVAX $4,845.21
- SNSE N/A
- Revenue Next Year
- EVAX $30.30
- SNSE N/A
- P/E Ratio
- EVAX N/A
- SNSE N/A
- Revenue Growth
- EVAX N/A
- SNSE N/A
- 52 Week Low
- EVAX $1.28
- SNSE $0.38
- 52 Week High
- EVAX $13.61
- SNSE $1.94
- Technical
- Relative Strength Index (RSI)
- EVAX 27.04
- SNSE 50.64
- Support Level
- EVAX $1.28
- SNSE $0.43
- Resistance Level
- EVAX $1.80
- SNSE $0.53
- Average True Range (ATR)
- EVAX 0.27
- SNSE 0.06
- MACD
- EVAX -0.08
- SNSE -0.00
- Stochastic Oscillator
- EVAX 12.16
- SNSE 58.24
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.